Compare Citius Pharmaceuticals Inc (CTXR) vs Chevron Corp (CVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Chevron Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Chevron Corp trades at $211.98 (market cap $414.98B). The key difference: Chevron Corp is far larger — about 30468.4× Citius Pharmaceuticals Inc's market cap, and Chevron Corp pays a 3.37% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Chevron Corp for 101 Days on average.
| CTXR | CVX | |
|---|---|---|
Market Cap | $13.62M | $414.98B |
Volume | 132,438 | 7,575,112 |
Sector | Health | Energy |
52-Week High | $1.82 | $217.73 |
52-Week Low | $0.48 | $146.72 |
Typical Hold Time | 17 Days | 101 Days |
Enterprise Value | $3.79M | $443.52B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
CVX trades at $211.605, up 3.13% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust cash flow from operations of $33.94B in 2025 and a dividend of $1.78 per share. However, revenue and net income have declined from 2022 peaks, with 2025 revenue at $184.43B and net income at $12.30B. Analyst consensus is bullish with a $208.31 price target, though geopolitical tensions and oil price volatility pose risks.
The outlook for CVX is cautiously optimistic, driven by high oil prices and strategic investments like the $13.8B Argentina project. Investment opportunities include a solid dividend yield and potential upside from production growth. Key risks are exposure to fluctuating oil prices, geopolitical instability affecting supply chains, and declining profit margins. Investors should weigh strong cash generation against cyclical industry pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
